Ocular Therapeutix, Inc.
11.48-0.05 (-0.43%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · OCUL · USD
Key Stats
Market Cap
2.43BP/E (TTM)
-Basic EPS (TTM)
-1.26Dividend Yield
0%Recent Filings
8-K
OCUL prices $446M stock offering
Ocular Therapeutix priced an underwritten offering of 37,909,018 common shares at $12.53 each on September 30, 2025, expecting to close October 1 and raise net proceeds of $445.9 million. The funds will support AXPAXLI's open-label extension for wet AMD, Phase 3 trials for NPDR, manufacturing investments, and pre-commercialization efforts. Cash runway extends into 2028, yet excludes full AXPAXLI launch costs. Assumptions may falter.
8-K
AXPAXLI program updates announced
Ocular Therapeutix announced updates on September 30, 2025, for its AXPAXLI program targeting wet AMD and NPDR. The SOL-1 Phase 3 trial completed randomization of 344 subjects and boasts over 95% retention with no new safety signals; topline data expected Q1 2026. SOL-R enrollment finished, results due first half 2027. Plans for HELIOS-2 and HELIOS-3 Phase 3 trials in NPDR secured FDA SPA agreements. A new U.S. patent allowance extends IP to 2044. Trials advance, but outcomes remain uncertain.
8-K
Q2 results and trial updates
Ocular Therapeutix reported Q2 2025 net revenue of $13.5 million, down 18.1% from $16.4 million last year due to tougher DEXTENZA reimbursement, yet unit sales rose 5% and cash hit $391 million after raising $97 million via ATM. SOL-1 Phase 3 wet AMD trial stays on track for Q1 2026 topline data, with SOL-R streamlined for 1H 2027 readout and a single long-term extension planned. Cash runway extends into 2028. Trials advance boldly.
10-Q
Q2 FY2025 results
Ocular Therapeutix posted Q2 revenue of $13.5M, down 18% y/y from $16.4M but up slightly q/q (derived), driven by DEXTENZA sales amid pricing adjustments and MIPS impacts that tempered demand yet lifted in-market units 5% y/y to 44,000. R&D costs surged 77% y/y to $51.1M on AXPAXLI Phase 3 trials, widening operating loss to $67.6M from $43.6M, while net loss hit $67.8M versus $43.8M last year, with the gap mainly from higher stock-based comp and fair-value changes. Cash dipped to $391M from $392M at year-end, buoyed by $94M equity raise, with $70M debt due 2029 at SOFR+6.75% and $20M liquidity covenant met; FCF not disclosed in the 10-Q. SOL-1 topline looms in Q1 2026. Regulatory hurdles could snag AXPAXLI approval.
8-K
Stockholders approve plans; trial enrolls
Ocular Therapeutix stockholders approved key governance measures at the June 11, 2025 annual meeting, including Amendment No. 4 adding 8,750,000 shares to the 2021 Stock Incentive Plan and 2,000,000 shares to the Amended 2014 Employee Stock Purchase Plan, while ratifying PwC as auditors. This unlocked vesting for CEO Pravin Dugel's performance option on 2,750,000 shares at $7.44 each, tied to stock hurdles. Enrollment wrapped in the SOL-R Phase 3 trial for AXPAXLI in wet AMD on May 31, securing 555 randomized subjects. Yet risks loom if FDA balks at trial data.
AXIM
Axim Biotechnologies, Inc.
0.01+0.00
EYPT
EyePoint Pharmaceuticals, Inc.
11.73-0.52
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
KLRS
Kalaris Therapeutics, Inc.
4.87-0.13
KPRX
Kiora Pharmaceuticals, Inc.
2.53+0.08
LYRA
Lyra Therapeutics, Inc.
5.83-0.12
OCS
Oculis Holding AG
21.55+0.55
OPT
Opthea Limited
3.41+0.00
OTLK
Outlook Therapeutics, Inc.
1.28-0.05
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00